Barinthus Biotherapeutics (BRNS)

• Market cap: $23.2M
• 1 day: -4.85%
• 5 days: -6.56%
• 1 month: -3.75%
• 3 months: -25.38%
• 6 months: -65.76%
• Year to date: -26.39%
• 1 year: -20.44%
• 5 years: -96.16%
• 10 years: -96.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Employees: 14